» Articles » PMID: 19258277

Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium Solani As Evidenced by Hybrid Expression in Saccharomyces Cerevisiae

Overview
Specialty Pharmacology
Date 2009 Mar 5
PMID 19258277
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The opportunistic mold Fusarium solani is intrinsically resistant to cell wall synthesis-inhibiting echinocandins (ECs), including caspofungin and micafungin. Mutations that confer acquired EC resistance in Saccharomyces cerevisiae and other normally susceptible yeast species have been mapped to the Fks1 gene; among these is the mutation of residue 639 from Phe to Tyr (F639Y) within a region designated hot spot 1. Fks1 sequence analysis identified the equivalent of Y639 in F. solani as well as in Scedosporium prolificans, another intrinsically EC-resistant mold. To test its role in intrinsic EC resistance, we constructed Fks1 hybrids in S. cerevisiae that incorporate F. solani hot spot 1 and flanking residues. Hybrid construction was accomplished by a PCR-based method that was validated by studies with Fks1 sequences from EC-susceptible Aspergillus fumigatus and paired EC-susceptible and -resistant Candida glabrata isolates. In support of our hypothesis, hybrid Fks1 incorporating F. solani hot spot 1 conferred significantly reduced EC susceptibility, 4- to 8-fold less than that of wild-type S. cerevisiae and 8- to 32-fold less than that of the same hybrid with an F639 mutation. We propose that Fks1 sequences represent determinants of intrinsic EC resistance in Fusarium and Scedosporium species and, potentially, other fungi.

Citing Articles

Favourable outcome of prosthetic valve endocarditis in a patient with an Ebstein anomaly.

Lee-Jones S, van der Westhuizen S, Taljaard J, Govender N, Razack R S Afr J Infect Dis. 2025; 40(1):699.

PMID: 40060086 PMC: 11886575. DOI: 10.4102/sajid.v40i1.699.


Fungicide resistance in Fusarium species: exploring environmental impacts and sustainable management strategies.

Naqvi S, Farhan M, Ahmad M, Kiran R, Shahbaz M, Abbas A Arch Microbiol. 2025; 207(2):31.

PMID: 39792175 DOI: 10.1007/s00203-024-04219-6.


The antifungal protein NFAP2 has low potential to trigger resistance development in .

Bende G, Zsindely N, Laczi K, Kristoffy Z, Papp C, Farkas A Microbiol Spectr. 2024; 13(1):e0127324.

PMID: 39560388 PMC: 11705825. DOI: 10.1128/spectrum.01273-24.


Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.

Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T Clin Microbiol Rev. 2024; 37(2):e0007423.

PMID: 38602408 PMC: 11237431. DOI: 10.1128/cmr.00074-23.


Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.

Neoh C, Chen S, Lanternier F, Tio S, Halliday C, Kidd S Clin Microbiol Rev. 2024; 37(2):e0000423.

PMID: 38551323 PMC: 11237582. DOI: 10.1128/cmr.00004-23.


References
1.
Perlin D . Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007; 10(3):121-30. PMC: 2696280. DOI: 10.1016/j.drup.2007.04.002. View

2.
Laverdiere M, Lalonde R, Baril J, Sheppard D, Park S, Perlin D . Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006; 57(4):705-8. DOI: 10.1093/jac/dkl022. View

3.
Cleary J, Garcia-Effron G, Chapman S, Perlin D . Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother. 2008; 52(6):2263-5. PMC: 2415792. DOI: 10.1128/AAC.01568-07. View

4.
Richardson M, Lass-Florl C . Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008; 14 Suppl 4:5-24. DOI: 10.1111/j.1469-0691.2008.01978.x. View

5.
KURTZ M, Rex J . Glucan synthase inhibitors as antifungal agents. Adv Protein Chem. 2001; 56:423-75. DOI: 10.1016/s0065-3233(01)56011-8. View